AlphAIAlphAI — Financial news for AI agents
investing.com$CYRX

Needham raises CryoPort stock price target to $28 on revenue beat

Needham raised its price target for CryoPort (NASDAQ:CYRX) to $28 from $19, citing strong Q3 2026 revenue performance and raised full-year guidance. The company reported 14% year-over-year revenue growth to $50.2M, exceeding estimates, but posted a wider-than-expected loss of $0.25 per share. Needham maintains a Buy rating, expecting further upside in 2027.

Original reporting
investing.com
Published Nov 6, 2026, 10:44 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 10:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CYRX
Bullish
high confidence
Mentioned
$CYRX
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CYRXBullishMed
01

Why it matters

The earnings beat and raised guidance prompted Needham to lift its price target, indicating a bullish short‑term outlook.

02

Market read

Analyst upgrade on a micro‑cap after earnings beat could drive short‑term buying interest.

03

What to watch

Potential cash‑burn and need for additional financing could limit upside.

Relevance 6/10Novelty 6/10Timing: after-hours reaction

Background

CryoPort reported Q3 2026 revenue of $50.2 million, beating forecasts, but posted a wider loss per share.

Company-level read

Ticker impact

$CYRXBullishHigh confidence
Context

Needham raised its price target on CryoPort to $28 after the company reported Q3 2026 revenue beating estimates.

Expected impact

upward pressure as the market prices in the higher target and revenue beat.

Evidence & confidence

The price‑target lift and revenue beat are fresh, material information for a micro‑cap stock.

Market effects

Sector

Positive signal for the biotech logistics sector, may lift peers.

Regional

Limited to US small‑cap biotech logistics niche.

Global

Low global impact.

Counterpoint

What could challenge this read

The price target may be overly optimistic given the company's ongoing losses.

Key entities

  • company
    CryoPort

    Biotech logistics provider listed on NASDAQ.

  • analyst
    Needham

    Equity research firm that raised the price target.

Read at source← All news

Related articles

$CYRXMed

CryoPort Q3 Earnings Call Highlights

CryoPort reported Q3 supporting 23 commercial therapies and 788 clinical trials. China operations contribute 3-4% of revenue. The company expects five regulatory filings and two potential new therapy approvals in 2026. Guidance is conservative, focusing on existing clients. Expansion plans include new BioServices capabilities in Paris and California, with long-term margin goals of 55% gross and 30% adjusted EBITDA.

finance.yahoo.com
$CYRXMed

Cryoport Reports Third Quarter 2026 Financial Results

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Third Quarter 2026 Financial Results · Third quarter revenue grew 14% year-over-year to $50.2 million · Commercial Cell and Gene Therapy revenue increased 20% year-over-year · Supporting a record 788 global clinical trials and 23 commercially approve

SEC EDGAR 8-K
$CYRXMedAI 8/10

Cryoport (CYRX) Q2 2026 Earnings Call Transcript

Cryoport (CYRX) reported Q2 2026 revenue of $49 million, up from prior periods, led by Life Science Services. Life Science Services revenue rose 15% year over year, with biostorage and bioservices up 25%. Support for commercial cell and gene therapy rose 9% to $9.4 million. Adjusted EBITDA turned positive at $0.4 million. Full-year 2026 revenue guidance remains $192 million to $196 million.

yahoo.com
$CYRXMed

Cryoport Reports Second Quarter 2026 Financial Results

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results · Second quarter revenue grew 8% year-over-year to $49.0 million · Life Sciences Services revenue increased 15% year-over-year · BioStorage/BioServices revenue grew 25% year-over-year · Supporting 779 global clin

SEC EDGAR 8-K
$RVMDMedAI 8/10

Why is Revolution Medicines stock surging today?

Revolution Medicines (RVMD) stock rose 7% after reporting Q3 revenue of $197.6M, exceeding estimates, driven by its new drug RASONQUE. Analysts raised price targets, with HC Wainwright setting a $350 target. The company has strong cash reserves and reaffirmed its 2026 expense guidance. NASDAQ and S&P 500 gains provided a supportive market backdrop.

investing.com
$AQNHighAI 8/10

Algonquin Power (AQN) Q3 2026 Earnings Call Transcript

Algonquin Power (AQN) reported Q3 2026 earnings. GAAP earnings were $57.6M, down from $71M last year. Adjusted earnings rose to $88.1M from $69M. The company highlighted progress in regulatory filings, asset sales, and rate case resolutions. AQN remains on track to meet its $0.35-$0.37 per share net EPS guidance for 2026. The company's balance sheet is stable, with $1.2B in liquidity and a BBB credit rating. AQN is advancing its redomicile to the U.S. and focusing on long-term value creation.

finance.yahoo.com